AstraZeneca's Vaccine Data Is Still Good Enough for U.S. Authorization

AstraZeneca (NASDAQ: AZN) created some drama releasing interim COVID-19 vaccine results just days before the pharma was able to generate final results from the U.S.-based phase 3 study. In this video from Motley Fool Live, recorded on March 29, Fool.com contributors Brian Orelli and Keith Speights discuss the brouhaha, and what it means for AstraZeneca's long-term prospects.

Continue reading

Source Fool.com